JP2011502985A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011502985A5 JP2011502985A5 JP2010532063A JP2010532063A JP2011502985A5 JP 2011502985 A5 JP2011502985 A5 JP 2011502985A5 JP 2010532063 A JP2010532063 A JP 2010532063A JP 2010532063 A JP2010532063 A JP 2010532063A JP 2011502985 A5 JP2011502985 A5 JP 2011502985A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- composition
- therapeutic agents
- compound
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims description 19
- 229940124597 therapeutic agent Drugs 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 6
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 6
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 6
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 6
- 229960001467 bortezomib Drugs 0.000 claims description 6
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 6
- 229960003957 dexamethasone Drugs 0.000 claims description 6
- 229960002949 fluorouracil Drugs 0.000 claims description 6
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 6
- 229960004768 irinotecan Drugs 0.000 claims description 6
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 6
- 229960001756 oxaliplatin Drugs 0.000 claims description 6
- 229960003787 sorafenib Drugs 0.000 claims description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 2
- 208000014767 Myeloproliferative disease Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 210000000601 blood cell Anatomy 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 201000006491 bone marrow cancer Diseases 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000004696 endometrium Anatomy 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 210000003128 head Anatomy 0.000 claims description 2
- 230000002489 hematologic effect Effects 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 210000001165 lymph node Anatomy 0.000 claims description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 2
- 229960001924 melphalan Drugs 0.000 claims description 2
- 210000003739 neck Anatomy 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 210000000813 small intestine Anatomy 0.000 claims description 2
- 210000000952 spleen Anatomy 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 230000002195 synergetic effect Effects 0.000 claims description 2
- 210000001550 testis Anatomy 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 210000003238 esophagus Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 15
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US157507P | 2007-11-02 | 2007-11-02 | |
| PCT/US2008/012385 WO2009061373A1 (en) | 2007-11-02 | 2008-10-31 | Combination therapy with organic arsenicals |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013165982A Division JP2013227347A (ja) | 2007-11-02 | 2013-08-09 | 有機ヒ素剤を使用する併用療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011502985A JP2011502985A (ja) | 2011-01-27 |
| JP2011502985A5 true JP2011502985A5 (enExample) | 2012-12-06 |
Family
ID=40626049
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010532063A Pending JP2011502985A (ja) | 2007-11-02 | 2008-10-31 | 有機ヒ素剤を使用する併用療法 |
| JP2013165982A Withdrawn JP2013227347A (ja) | 2007-11-02 | 2013-08-09 | 有機ヒ素剤を使用する併用療法 |
| JP2014053434A Pending JP2014111666A (ja) | 2007-11-02 | 2014-03-17 | 有機ヒ素剤を使用する併用療法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013165982A Withdrawn JP2013227347A (ja) | 2007-11-02 | 2013-08-09 | 有機ヒ素剤を使用する併用療法 |
| JP2014053434A Pending JP2014111666A (ja) | 2007-11-02 | 2014-03-17 | 有機ヒ素剤を使用する併用療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US8252773B2 (enExample) |
| EP (1) | EP2209480B1 (enExample) |
| JP (3) | JP2011502985A (enExample) |
| KR (1) | KR20100100835A (enExample) |
| CN (1) | CN101903029B (enExample) |
| AU (1) | AU2008325243B2 (enExample) |
| CA (1) | CA2704395A1 (enExample) |
| ES (1) | ES2392737T3 (enExample) |
| WO (1) | WO2009061373A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007027344A2 (en) * | 2005-07-29 | 2007-03-08 | Ziopharm Oncology, Inc. | Compounds and methods for the treatment of cancer |
| ES2703740T3 (es) * | 2008-08-20 | 2019-03-12 | Solasia Pharma K K | Compuestos de organoarsénico y procedimientos para el tratamiento del cáncer |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2349729A (en) * | 1940-08-24 | 1944-05-23 | Parke Davis & Co | Therapeutic arsenic preparation |
| EP1391206B1 (en) * | 1997-10-15 | 2008-07-02 | Polarx Biopharmaceuticals, Inc. | Pharmaceutical compositions comprising arsenic trioxide for the treatment of non-Hodgkin's lymphoma |
| ID25622A (id) | 1997-11-10 | 2000-10-19 | Sloan Kettering Inst Cancer | Proses untuk memproduksi formulasi arsenat trioksida dan metoda untuk mengobati kanker dengan menggunakan arsenat trioksida atau melarsoprol |
| CN1233476A (zh) * | 1998-04-24 | 1999-11-03 | 陆道培 | 治疗急性白血病的药物及其制备方法 |
| EP1002537A1 (en) | 1998-10-30 | 2000-05-24 | Assistance Publique, Hopitaux De Paris | Use of melarsoprol for the manufacture of a medicament for treating B-cell lymphoproliferative diseases, such as multiple myeloma |
| US6191123B1 (en) * | 1999-03-19 | 2001-02-20 | Parker Hughes Institute | Organic-arsenic compounds |
| CA2406081C (en) * | 2000-04-26 | 2009-12-22 | Oregon Health Sciences University | Administration of a thiol-based chemoprotectant compound |
| AU2003207455B2 (en) * | 2002-01-07 | 2007-09-20 | Board Of Regents, The University Of Texas System | S-dimethylarsino-thiosuccinic acid S-dimethylarsino-2-thiobenzoic acid S-(dimethylarsino) glutathione as treatments for cancer |
| US20050176696A1 (en) * | 2003-12-08 | 2005-08-11 | Regents Of The University Of Arizona | Synergistic anit-cancer compounds |
| TW200538149A (en) * | 2004-05-20 | 2005-12-01 | Telik Inc | Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound |
| TWI411431B (zh) * | 2004-07-16 | 2013-10-11 | Texas A & M Univ Sys | 有機砷化合物、其用於治療癌症之用途及包含其之醫藥組成物 |
| WO2007027344A2 (en) * | 2005-07-29 | 2007-03-08 | Ziopharm Oncology, Inc. | Compounds and methods for the treatment of cancer |
| TW200829261A (en) | 2006-09-29 | 2008-07-16 | Ziopharm Oncology Inc | Method for controlling angiogenesis in animals |
-
2008
- 2008-10-31 EP EP08848529A patent/EP2209480B1/en not_active Not-in-force
- 2008-10-31 US US12/740,661 patent/US8252773B2/en not_active Expired - Fee Related
- 2008-10-31 KR KR1020107011723A patent/KR20100100835A/ko not_active Ceased
- 2008-10-31 ES ES08848529T patent/ES2392737T3/es active Active
- 2008-10-31 JP JP2010532063A patent/JP2011502985A/ja active Pending
- 2008-10-31 AU AU2008325243A patent/AU2008325243B2/en not_active Ceased
- 2008-10-31 CA CA2704395A patent/CA2704395A1/en not_active Abandoned
- 2008-10-31 CN CN2008801142801A patent/CN101903029B/zh not_active Expired - Fee Related
- 2008-10-31 WO PCT/US2008/012385 patent/WO2009061373A1/en not_active Ceased
-
2012
- 2012-07-26 US US13/559,036 patent/US20120295861A1/en not_active Abandoned
-
2013
- 2013-03-06 US US13/786,591 patent/US20130261082A1/en not_active Abandoned
- 2013-08-09 JP JP2013165982A patent/JP2013227347A/ja not_active Withdrawn
-
2014
- 2014-03-17 JP JP2014053434A patent/JP2014111666A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3277276B1 (en) | Methods of administering glutaminase inhibitors | |
| Yoshioka et al. | A new combination chemotherapy with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for advanced esophageal cancers | |
| CA2990192A1 (en) | Compositions and methods for inhibiting arginase activity | |
| JP2008528671A5 (enExample) | ||
| JP2010533206A5 (enExample) | ||
| JP2014500295A5 (enExample) | ||
| US9370535B2 (en) | Method for treatment of advanced solid tumors | |
| JP2008506710A5 (enExample) | ||
| TWI641374B (zh) | 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
| JP6878431B2 (ja) | がんに対するメルフルフェン投薬計画 | |
| JP2007500201A (ja) | エクチナサイジン−７４３と白金抗腫瘍化合物との併用 | |
| JP2014516075A (ja) | 癌治療のためのメタロセン化合物の使用 | |
| CN101107001A (zh) | 配合有α,α,α-三氟胸苷和胸苷磷酸化酶抑制剂的抗癌剂 | |
| CN110845408A (zh) | 同位素富集的乐伐替尼 | |
| JP2011502985A5 (enExample) | ||
| CN1367690A (zh) | 使用五氟苯磺酰胺的综合疗法 | |
| JP2013227347A5 (enExample) | ||
| TWI615145B (zh) | 含伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
| TW202011946A (zh) | 以bet抑制劑及蛋白酶體抑制劑之組合療法 | |
| JP2011514356A5 (enExample) | ||
| WO2013137433A1 (ja) | ３剤を組み合わせた新規な抗腫瘍剤 | |
| JP2009527463A5 (enExample) | ||
| TW201943687A (zh) | 包含4-苯丁酸衍生物及類鴉片的組成物 | |
| WO2009139085A1 (ja) | 抗腫瘍剤、キット及び癌治療方法 | |
| TWI307628B (en) | Use of zd0473 in combination with a non-platinum based anti-cancer agent |